Abstract: Prostaglandin-type compounds with one or two fluoro substituents at the C-16 position are disclosed, with processes for making them. These compounds are useful for a variety of pharmacological purposes, including anti-ulcer, inhibition of platelet aggregation, increase of nasal patency, labor inducement at term, and wound healing.

Abstract: Prostaglandin-type compounds with one or two fluoro substituents at the C-16 position are disclosed, with processes for making them. These compounds are useful for a variety of pharmacological purposes, including anti-ulcer, inhibition of platelet aggregation, increase of nasal patency, labor inducement at term, and wound healing.

Abstract: Tricyclic cyanoepoxides of the formula ##SPC1##Wherein R.sub.12 is ##EQU1## or ##SPC2##Wherein CgH.sub.2g, R.sub.13, R.sub.14, s, T, Z, and .about. are as defined hereinafter; ##SPC3##Wherein R.sub.21 is a blocking group as defined hereinafter; and ##SPC4##Together with processes for preparing them. The cyanoepoxides are useful intermediates in preparing prostaglandins and prostaglandin analogs having pharmacological utility.

Abstract: Prostaglandin-type compounds with one or two fluoro substituents at the C-16 position are disclosed, with processes for making them. These compounds are useful for a variety of pharmacological purposes, including anti-ulcer, inhibition of platelet aggregation, increase of nasal patency, labor inducement at term, and wound healing.

Abstract: Oxazolidines having the formula ##SPC1##Wherein .about. indicates endo or exo attachment, but differing in their stereoisomeric configuration, are prepared by reaction of the isomers of a tricyclic lactone aldehyde of the formula ##SPC2##Wherein .about. is as defined above, with d- or l-ephedrine; useful for separating optically active isomers of the aldehyde.

Abstract: Substituted phenyl and naphthyl esters of PGA.sub.1, 15-alkyl-PGA.sub.1, and 15(R)-15-alkyl-PGA.sub.1, and their racemic forms, and processes for producing them are disclosed. The products are useful for the same pharmacological and medical purposes as PGA.sub.1, 15-alkyl-PGA.sub.1, and 15(R)-15-alkyl-PGA.sub.1, and are also useful as a means for obtaining highly purified PGA.sub.1, 15-alkyl-PGA.sub.1, and 15(R)-15-alkyl-PGA.sub.1 products.

Abstract: Prostaglandin-type compounds with one or two fluoro substituents at the C-16 position are disclosed, with processes for making them. These compounds are useful for a variety of pharmacological purposes, including anti-ulcer, inhibition of platelet aggregation, increase of nasal patency, labor inducement at term, and wound healing.

Abstract: Prostaglandin-type compounds with one or two fluoro substituents at the C-16 position are disclosed, with processes for making them. These compounds are useful for a variety of pharmacological purposes, including anti-ulcer, inhibition of platelet aggregation, increase of nasal patency, labor inducement at term, and wound healing.

Abstract: Prostaglandin-type compounds with one or two fluoro substituents at the C-16 position are disclosed, with processes for making them. These compounds are useful for a variety of pharmacological purposes, including anti-ulcer, inhibition of platelet aggregation, increase of nasal patency, labor inducement at term, and wound healing.

Abstract: This invention is a group of 8-beta, 12-alpha-PG.sub.2 (prostaglandin-type) analogs having variable chain length, or methyl or phenyl substitution in the hydroxy-substituted side-chain, and processes for making them. These compounds are useful for a variety of pharmacological purposes, including anti-ulcer, inhibition of platelet aggregation, increase of nasal patency, and labor inducement at term.

Abstract: Prostaglandin-type compounds with one or two fluoro substituents at the C-16 position are disclosed, with processes for making them. These compounds are useful for a variety of pharmacological purposes, including anti-ulcer, inhibition of platelet aggregation, increase of nasal patency, labor inducement at term, and wound healing.

Abstract: Prostaglandin-type compounds with one or two fluoro substituents at the C-16 position are disclosed, with processes for making them. These compounds are useful for a variety of pharmacological purposes, including anti-ulcer, inhibition of platelet aggregation, increase of nasal patency, labor inducement at term, and wound healing.

Abstract: Prostaglandin-type compounds with one or two fluoro substituents at the C-16 position are disclosed, with processes for making them. These compounds are useful for a variety of pharmacological purposes, including anti-ulcer, inhibition of platelet aggregation, increase of nasal patency, labor inducement at term, and wound healing.

Abstract: Substituted phenyl and naphthyl esters of PGE.sub.1, 15-alkyl-PGE.sub.1, and 15(R)-15-alkyl-PGE.sub.1, and their racemic forms, and processes for producing them are disclosed. The products are useful for the same pharmacological and medical purposes as PGE.sub.1, 15-alkyl-PGE.sub.1, and 15(R)-15-alkyl-PGE.sub.1, and are also useful as a means for obtaining highly purified PGE.sub.1, 15-alkyl-PGE.sub.1, and 15(R)-15-alkyl-PGE.sub.1 products.

Abstract: 5-Oxa-11-deoxy phenyl- and phenoxy-substituted prostaglandin type compounds and processes for making them. These compounds are useful for a variety of pharmacological purposes, including anti-ulcer, inhibition of platelet aggregation, increase of nasal patency, labor inducement at term, and wound healing.

Abstract: 5-oxa-11-deoxyphenyl- and phenoxy-substituted prostaglandin- type compounds and processes for making them. These compounds are useful for a variety of pharmacological purposes, including inhibition of platelet aggregation, increase of nasal patency, and labor inducement at term.

Abstract: Oxazolidines having the formula ##SPC1##Wherein .about. indicates endo or exo attachment, but differing in their stereoisomeric configuration, prepared by reaction of the isomers of an oxo compound of the formula ##SPC2##Wherein .about. is as defined above, with d- or l-ephedrine; useful for separating optically active isomers of the oxo compound.

Abstract: Process for preparing lactones of the formula ##SPC1##Wherein G is R.sub.9, 1-hydroxyhexyl, or 1-hydroxy-cis-3-hexenyl, wherein R.sub.9 is hydrogen, alkyl of one to 12 carbon atoms, inclusive, cycloalkyl of 3 to 10 carbon atoms, inclusive, aralkyl of 7 to 12 carbon atoms, inclusive, phenyl, or phenyl substituted with one, 2, or 3 alkyl of one to 4 carbon atoms, inclusive; wherein M is hydrogen or a blocking group; wherein R.sub.1 is hydrogen, alkyl of one to 12 carbon atoms, inclusive, cycloalkyl of 3 to 10 carbon atoms, inclusive, aralkyl of 7 to 12 carbon atoms, inclusive, phenyl, or phenyl substituted with one, 2, or 3 chloro or alkyl of one to 4 carbon atoms, inclusive, or ethyl substituted in the .beta.-position with 3 chloro, 2 or 3 bromo, or 1, 2, or 3 iodo; and wherein .about. indicates attachment in alpha or beta configuration. The lactones are useful intermediates in preparing prostaglandins having pharmacological utility.

Abstract: Substituted phenyl and naphthyl esters of PGA.sub.2, 15-alkyl-PGA.sub.2, and 15(R)-15-alkyl-PGA.sub.2, and their racemic forms, and processes for producing them are disclosed. The products are useful for the same pharmacological and medical purposes as PGA.sub.2, 15-alkyl-PGA.sub.2, and 15(R)-15-alkyl-PGA.sub.2, and are also useful as a means for obtaining highly purified PGA.sub.2, 15-alkyl-PGA.sub.2, and 15(R)-15-alkyl-PGA.sub.2 products.

Abstract: Prostaglandin-type compounds with one or two fluoro substituents at the C-16 position are disclosed, with processes for making them. These compounds are useful for a variety of pharmacological purposes, including anti-ulcer, inhibition of platelet aggregation, increase of nasal patency, labor inducement at term, and wound healing.